Article Sidebar
Views PDF: 274
SIDE EFFECTS OF ADJUVANT CHEMOTHERAPY USING XELOX REGIMEN FOR COLON CANCER STAGE II,III AT DA NANG HOSPITAL
Main Article Content
Abstract
Objectives: Describe some clinical and subclinical characteristics of patients with stage II, III colon cancer at Da Nang hospital and evaluate the slide effects of adjuvant chemotherapy with XELOX regimen in the study group of patients. Subjects and methods: Descriptive clinical study with longitudinal follow-up on 66 patients diagnosed with high-risk stage II and stage III colon cancer treated at Danang Hospital from June 2017 to June 2020 Results: The mean age of the patients was 59.98 ± 10.33, the age group from 50-59 and 60-69 had the highest rate at 34.8%. The most common tumor site was the hepatic flexure colon 22.7%, the sigmoid colon 37.9%, moderate differentiation had the rate of 74.2%. Most of the treatment toxicity is in grade 1-2, rate of toxicity grade 3-4 on hematology, Hepatotoxicity, hand foot syndrome, peripheral neurotoxicity has the rate of 3%-4.5%. Conclusions: XELOX regimen is safe in adjuvant therapy in the study group of patients with mild side effects.
Article Details
Keywords
Colon cancer, XELOX
References
2. Quasar Collaborative Group, Gray R., Barnwell J. và cộng sự. (2007). Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 370(9604), 2020–2029.
3. Schmoll H.-J., Tabernero J., Maroun J. và cộng sự. (2015). Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol, 33(32), 3733–3740.
4. André T., Boni C., Mounedji-Boudiaf L. và cộng sự. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350(23), 2343–2351.
5. Võ Văn Kha (2017), Đánh giá kết quả hóa trị bổ trợ phác đồ XELOX trong ung thư biểu mô tuyến đại tràng giai đoạn II, III, Luận án tiến sĩ y học, Đại Học Y Hà Nội.
6. Nguyễn Thị Thúy Hằng (2013), Nhận xét một số đặc điểm lâm sàng, cận lâm sàng và độc tính của phác đồ XELOX điều trị bổ trợ ung thư đại tràng giai đoạn III, Luận văn bác sĩ nội trú, Đại Học Y Hà Nội, Hà Nội.
7. Danno K., Hata T., Tamai K. và cộng sự. (2017). Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer. Cancer Chemother Pharmacol, 80(4), 777–785.